1 Title

- 2 Adaptive design methods in dialysis clinical trials a systematic review
- 3
- 4 Authors (first name, middle initial and last names)
- 5 Conor Judge, M.B., BEng. (1) (2) (3)
- 6 Robert Murphy, M.B. (1)
- 7 Catriona Reddin, M.B. (1)
- 8 Sarah Cormican, M.B. (1) (3)
- 9 Andrew Smyth, M.B., Ph.D. (1)
- 10 Martin O'Halloran, BEng., Ph.D. (2)
- 11 Martin J O'Donnell, M.B., Ph.D. (1)
- 12
- 13 Running Title (35 characters including spaces)
- 14 Adaptive design methods in dialysis
- 15
- 16 Author affiliations (including division and/or department)
- 17 (1) HRB-Clinical Research Facility Galway, NUI Galway, Galway, Ireland
- 18 (2) Translational Medical Device Lab, NUI Galway, Galway, Ireland
- 19 (3) Wellcome Trust HRB, Irish Clinical Academic Training
- 20

- 21 Word Count Abstract
- 22 270
- 23 Word Count Text
- 24 3060
- 25 Corresponding Author
- 26 Dr Conor Judge, HRB-Clinical Research Facility Galway, National University of Ireland Galway,
- 27 Newcastle Road, Galway, Ireland, H91YR71 Email: conorjudge@gmail.com

28 Key Words

29 Dialysis, Adaptive design, Haemodialysis, Peritoneal Dialysis, End Stage Kidney Disease

30 Significance statement

31 What was previously known about the specific topic of the manuscript?

- 32 The use of adaptive designs methods in dialysis trials is unquantified.
- 33 What were the most important findings? If studies are animals, this should be specified.
- 34 Although absolute numbers of adaptive design trials have increased over time, the proportion of
- dialysis trials using an adaptive design has reduced. Among trials that employed an adaptive design,
- 36 52% of dialysis trials were revised due to the adaptive criteria. Group sequential designs were the
- 37 most common type of adaptive design method used in dialysis randomized clinical trials. Acute
- 38 Kidney Injury (AKI) was studied in 54% of trials and End Stage Kidney Disease (ESKD) was studied in
- 39 44% of trials, which used an adaptive design.
- 40 How does the new information advance a new understanding of the kidney and its diseases?
- 41 Adaptive design methods are effective in dialysis trials, but their relative use has declined over time.

42 Word Count (120)

- 43 152 (including headings)
- 44

45 Abstract

46 Background

- 47 Adaptive design methods are intended to improve efficiency of clinical trials and are relevant to
- 48 evaluating interventions in dialysis populations. We sought to quantify the use of adaptive designs in
- 49 dialysis clinical trials.

50 Methods

51 We completed a full text systematic review and adhered to the Preferred Reporting Items for

- 52 Systematic Review and Meta-Analysis (PRISMA) guidelines. Our review utilised a machine learning
- 53 classifier and a novel full text systematic review method. We searched MEDLINE (Pubmed) and
- 54 performed a detailed data extraction of trial characteristics and a completed a narrative synthesis of
- 55 the data.

56 Results

57 50 studies, available as 66 articles, were included after full text review. 31 studies were conducted in 58 a dialysis population and 19 studies had renal replacement therapy as a primary or secondary 59 outcome. While the absolute number of adaptive design methods is increasing over time, the 60 relative use of adaptive design methods in dialysis trials is decreasing over time (6.1% in 2009 to 61 0.3% in 2019). Adaptive design methods impacted 52% of dialysis trials they were used in. Group 62 sequential designs were the most common type of adaptive design method used. Acute Kidney 63 Injury (AKI) was studied in 27 trails (54%), End Stage Kidney Disease (ESKD) was studied in 22 trials 64 (44%) and Chronic Kidney Disease (CKD) was studied in 1 trial (2%). 26 studies (52%) were supported 65 by public funding. 41 studies (82%) did not report their adaptive design method in the title or 66 abstract and would not be detected by a standard systematic.

67 Conclusions

- 68 Adaptive design methods are employed in dialysis trials, but there has been a decline in their relative
- 69 use over time.

70

- 71 Registration Number
- 72 PROSPERO: CRD42020163946
- 73
- 74 Word Count (300)
- 75 270

76 Introduction

77 Background

- 78 Randomized clinical trials are the gold standard for evaluating efficacy, futility or harm of new
- therapies (1). Compared to similar specialties, nephrology has traditionally had a low number of
- randomized clinical trials, particularly evident for patients with End Stage Kidney Disease (ESKD) (2).
- 81 The comparatively low number of trials are postulated to be due to difficult recruitment, previous
- history of underpowered trials and lack of funding (3,4). Although the number of trials are
- 83 increasing, nephrology continues to lag behind other specialities such as cardiology,
- 84 haematology/oncology and gastroenterology (5,6).
- 85 Adaptive clinical trials use interim data analyses to modify the trial design or duration in a
- 86 predefined way (7), without undermining the integrity or validity of the trial, thereby preserving the
- 87 Type 1 Error (False Positive) rate. The most common type of adaptive design is the Group Sequential
- 88 Design (GSD), where planned interim analyses permit stopping of trials for efficacy or futility. Other
- 89 designs include sample size re-estimation, multi-arm multi-stage trials, adaptive randomisation,
- 90 biomarker adaptive and seamless phase II/III trials (8).
- 91 Adaptive clinical trials appear particularly suitable for the evaluation of novel interventions in ESKD,
- 92 by reducing resource requirements, decreasing time to study completion and increasing the
- 93 likelihood of study success i.e. power to answer hypothesis (9). Previous trials in ESKD have overly
- 94 relied on observational data to inform trial design, including assumptions of expected effect size and
- 95 variance (10), rather than estimates from early phase clinical trials. If incorrect, trials may be
- 96 underpowered with an insufficient sample size to answer the underlying research question (10).
- 97 Adaptive sample size re-estimation is a potential solution, as seen in cardiology trials (11), such as
- 98 planned blinded sample size re-estimation, which identifies inaccurate assumptions, thereby
- 99 triggering altered recruitment targets mid trial to ensure adequate power.

100	Adaptive design may also be relevant to evaluation of more established interventions. For example,
101	the 4D trial (12) reported that atorvastatin 20mg per day did not reduce cardiovascular events in
102	ESKD despite evidence of a 20-30% reduction in other populations (13). This trial included a single
103	dose of statin or a single low-density lipoprotein target; it is hypothesised that alternative or
104	multiple doses may have been more beneficial in an ESKD population given the significantly altered
105	pharmacokinetics and pharmacodynamics (10,14). An adaptive multi-arm multi-stage (MAMS) trial
106	design may have been more appropriate with one interim analysis at the end of stage I to identify an
107	optimum dose to take forward into stage II. For example, the Telmisartan and Insulin Resistance in
108	HIV (TAILOR) trial used a MAMS design with one interim analysis to identify the most appropriate
109	dose among three telmisartan doses (20, 40 and 80mg daily). All three doses were tested in stage I
110	and telmisartan 80mg was taken forward into stage II (15).
111	This systematic review aims to: (i) summarise the use of adaptive design methodology in randomized
112	clinical trials in dialysis population and populations at risk of requiring dialysis; (ii) describe the
113	characteristics of the adaptive designs including dialysis modality, funding, and geographical
114	location; (iii) describe the adaptive trial design characteristics; (iv) estimate the percentage of
115	adaptive clinical trials in dialysis among all dialysis RCTs; and (v) outline temporal trends in all the
116	above.

117

118 Methods

- 119 We performed a systematic review, reported according to the Preferred Reporting Items for
- 120 Systematic Reviews and Meta-Analyses guidelines (PRISMA) (16). The protocol was registered with
- 121 PROSPERO (CRD42020163946) and published separately (17). After testing our pre-defined search
- 122 strategy (17), we found a small number (n=16) of dialysis RCTs that reported an adaptive design
- 123 method. We discovered that the adaptive design methods are often not reported in the title and
- abstract of papers and would not be detected in a traditional systematic search. To overcome this,
- 125 we developed a novel "full text systematic review" protocol and to our knowledge, this is the first
- use of this methodology.
- 127 Search method for the identification of trials
- 128 Electronic search Dialysis Studies
- 129 We performed an electronic search on MEDLINE (Pubmed) from database inception until 01 June
- 130 2020. Zotero was used as our reference manager. The dialysis search terms were adapted from
- 131 Beaubien-Souligny et al. 2019 (18) and included dialysis, peritoneal dialysis, hemodialysis,
- 132 hemodiafiltration, haemodiafiltration, hemofiltration, haemofiltration, extracorporeal blood
- 133 cleansing, haemodialysis, renal dialysis, renal replacement, end stage kidney, end stage renal, stage
- 134 5 kidney and stage 5 renal (Supplementary Table 1). The output was stored in the Research
- 135 Information Systems (RIS) file format.

136 Machine Learning Classifier – Randomized Clinical Trials

- 137 We used the high sensitivity machine learning classifier (RobotSearch) to identify RCTs from the
- dialysis search output (15). RobotSearch is a machine learning classification algorithm combining an
- 139 ensemble of Support Vector Machines (SVM) and Convolutional Neural Networks (CNN) with a
- reported Area Under the Curve of 0.987 (95% Confidence Interval (CI), 0.984 to 0.989) for RCT
- 141 classification. We adjusted the parameters of RobotSearch to perform a sensitive search to increase

- 142 the proportion of RCTs that are correctly identified (15). Studies classified as likely to be randomized
- 143 clinical trials were sourced for the full text systematic review.

144 Full text Systematic Review – Adaptive Design Methods

- 145 We used Recoll for Windows to perform a full text systematic review on our dialysis randomized
- clinical trial search results. Recoll is based on the Xapian search engine library and provides a
- 147 powerful text extraction layer and a graphical interface. The adaptive design search terms were
- adapted from Bothwell et al., 2018 (19) and included phase ii/iii, treatment switching, biomarker
- adaptive, biomarker adaptive design, biomarker adjusted, adaptive hypothesis, adaptive dose-
- 150 finding, pick-the-winner, drop-the-loser, sample size re-estimation, re-estimations, adaptive
- 151 randomization, group sequential, adaptive seamless, adaptive design, interim monitoring, bayesian
- adaptive, flexible design, adaptive trial, play-the-winner, adaptive method, adaptive AND dose AND
- adjusting, response adaptive, adaptive allocation, adaptive signature design, treatment adaptive,
- 154 covariate adaptive and sample size adjustment (Supplementary Table 2).

155 Manual full text review

- 156 We then performed manual full text review to confirm studies that were included in the final
- 157 systematic review. This process is summarised in a PRISMA flowchart (Figure 1). Full text review was
- 158 performed by CJ, RM and CR. Disagreements were resolved by consensus and where a resolution
- 159 was not reached by discussion, a consensus was reached through a third reviewer (MOD).

160 Inclusion/exclusion criteria for the selection of studies

161 Type of study design and participants

- 162 Randomized clinical trials of interventions in patients with ESKD, acute kidney injury undergoing
- 163 renal replacement therapy (RRT) including haemodialysis, peritoneal dialysis, haemodiafiltration and
- 164 haemofiltration. We did not limit our population to any specific disease. Additionally, we included
- studies that included dialysis as either a primary or secondary outcome.

166 Type of intervention and outcome

- 167 We did not place a restriction on the intervention type and included trials that studied medications
- 168 during dialysis, medical devices, dialysis parameters and dialysis modality. We included all outcomes
- 169 including surrogate markers, patient-centred outcomes and hard clinical outcomes.

170 Selection and analysis of trials

- 171 CJ, RM and CR extracted the study characteristics independently and in parallel. Data collected
- included the type of the adaptive design, stopping rule, impact of adaptive design (i.e., stopping for
- 173 futility or efficacy, sample size changes, etc.), trial population, intervention, dialysis modality, the
- 174 country of the lead investigator and the funder of the study (Adapted from Hatfield et al., 2016
- 175 (20))(Supplementary Table 3).

176 Assessment of the quality of the studies: risk of bias

- 177 We used the Cochrane Risk of Bias 2 Tool (21) to assess methodological quality of eligible trials
- 178 including random sequence generation, allocation concealment, blinding of participants and health
- 179 care personnel, blinded outcome assessment, completeness of outcome data, evidence of selective
- 180 reporting and other biases. Risk of bias assessments were performed independently by (CJ, RM, CR,
- 181 SC), and disagreements were resolved by consensus. If one or more domains was rated as high, the
- 182 study was considered at high risk of bias. We summarised our findings in a risk of bias table using the
- 183 Revised Cochrane risk-of-bias tool for randomized trials (22)(Supplementary Table 4).

184 Data synthesis

- 185 A descriptive synthesis of the data was performed. We reported overall outcomes and outcomes by
- 186 (i) frequency and type of adaptive design; (ii) adaptive designs as a proportion of studies classified as
- 187 dialysis RCTs by RobotSearch (iii) Population, Intervention and Outcome including dialysis modality
- 188 (haemodialysis, peritoneal dialysis, haemodiafiltration and haemofiltration); (iv) publication in high
- 189 impact journals; (v) geographic location and funding; (vi) reporting of adaptive design methods in
- title and abstract; and (vii) a risk of bias assessment.

191 Results

192	The systematic search of articles with dialysis keywords published before 01 June 2020, identified
193	209,033 results. 5,452 articles were classified as probable RCTs by the machine learning classifier
194	RobotSearch (15). Full text articles were sourced (n=5,022) and we performed a full text systematic
195	review using adaptive design keywords which identified 358 studies for manual screening. 50
196	studies, available as 66 articles, were included after full text review (Figure 1). 31 studies were
197	conducted in dialysis populations and 19 studies included RRT as a primary or secondary outcome.

198 Study characteristics

199 Frequency and type of Adaptive Design

- 200 Figure 2 reports the number of adaptive design designs by year and alongside the proportion of all
- 201 dialysis RCTs that used adaptive design methods. The absolute amount of dialysis trials using
- adaptive designs has increased each year, but this has not matched the overall increase in dialysis
- trials and resulted in a relative decrease over time in the use of adaptive design methods in dialysis

trials ranging from 6.1% in 2009 to 0.3% in 2019 with a mean of 1.76%.

- 205 Group sequential designs were the most common type of adaptive design method used, 31 (62%)
- trials (22 (71%) in dialysis populations and 9 (47.4%) in dialysis outcome trials) (Table 1). The O'Brien-
- 207 Fleming stopping boundary was the most common stopping rule, used in 8 trials (25.8%), followed
- by Lan DeMets used in 7 trials (22.6%). 18 trials (58.1%) were impacted by the use of group
- sequential adaptive design including 6 trials (33.3%) that stopped early for futility, 3 trials (16.7%)
- 210 that stopped early for efficacy and 4 trials (22.2%) that stopped early for safety. Sample-Size Re-
- estimation was the second most common type of adaptive design, used in 14 trials (28%) (8 (25.8%)
- in dialysis populations and 6 (31.6%) in dialysis outcome trials) (Table 2). 8 trials (57.1%) were
- impacted by the use of Sample-Size Re-estimation adaptive design including 5 trials (62.5%) that
- 214 increased sample size. Phase II/III seamless design was the third most common type of adaptive

design, 3 trials (6%) (1 (3.23%) in dialysis populations and 2 (10.52%) in dialysis outcome trials)

- 216 (Table 3). Adaptive Dose-Escalation and Interim analysis were used in one trial each.
- 217 Population, Intervention, and Outcome studied
- Acute Kidney Injury (AKI) was studied in 27 trials (54%), End Stage Kidney Disease (ESKD) was studied
- in 22 trials (44%) and Chronic Kidney Disease (CKD) was studied in 1 trial (2%). Figure 3 reports the
- 220 number of each population under study per year and shows a larger increase in adaptive design
- 221 methods in AKI populations compared to ESKD populations. Medications were the most common
- intervention type, evaluated in 28 trials (56%), followed by Dialysis Modality in 6 trials (12%), and
- 223 Dialysis Parameter in 4 trials (8%). Haemodialysis was the most common dialysis modality studied in
- 224 26 trials (52%), followed by Haemodialysis and haemodiafiltration in 8 trials (16%), Haemodialysis,
- haemodiafiltration and haemofiltration in 7 trials (14%) and Peritoneal Dialysis in 4 trials (8%). Hard
- clinical outcomes were selected in 30 trials (60%), followed by surrogate outcomes in 17 trials (34%)
- and mixed in 3 trials (6%). The outcome measure was continuous in 11 trials (22%) and dichotomous
- in 39 trials (78%). Phase III studies were the most common study phase, studied in 40 trials (80%)

229 (Table 1-3).

230 Publication in High Impact Journals

231 30 studies (60%) were published in a high impact journal (Impact Factor > 9). 13 studies (26%) were

232 published in the New England Journal of Medicine (NEJM), 5 studies (10%) were published in the

- Journal of the American Medical Association (JAMA), 4 studies (8%) were published in Trials, and 2
- studies (4%) were published in the Journal of the American Society of Nephrology (JASN).

235 Geographic location and Funding

The most common country of the lead author was the United States of America in 20 studies (40%),

- followed by Germany in 6 studies (12%), France in 4 studies (8%), The Netherlands in 4 studies (8%),
- Australia in 3 studies (6%), and the United Kingdom in 3 studies (6%) (Tables 1-3). 43 studies (86%)
- were multicentre trials. 26 studies (52%) were supported by public funding, 17 studies (34%) were

- supported by private funding, 5 studies (10%) were supported by both public and private funding
- and 2 studies (4%) did not report the source of funding.

242 Reporting of Adaptive Design Method in Title and Abstract

- 243 41 studies (82%) did not report their adaptive design method in the title or abstract and would not
- be detected by a standard systematic review search.
- 245

246 Risk of Bias

- 247 Risk of bias was assessed for forty trials (protocols were excluded) (Supplementary Figure 1,
- Supplementary Table 4). Overall risk of bias was deemed to be "low" in 17 trials (42.5%), "some
- concerns" in 13 trials (32.5%), and "high risk" in 10 trials (25%). The randomization process led to
- some concerns for 10 studies (25%). Deviations from intended interventions led to some concerns
- for 4 studies (10%) and "high risk" for 6 studies (15%). Missing outcome data were deemed to be
- 252 "some concerns" for 2 studies (5%) trials and 'high risk' of bias for 2 studies (5%). Measurement of
- 253 outcome measures were deemed to be "some concerns" for 2 studies (5%) trials and 'high risk' of
- bias for 1 study (2.5%). Selection of the reported result were deemed to be "some concerns" for 6
- studies (15%) trials and 'high risk' of bias for 1 study (2.5%).

256

257

258 **Discussion**

- 259 In this systematic review, we report that adaptive design methods were used in 50 dialysis
- randomized clinical trials over a 20-year period. While the absolute number has increased over time,
- the relative use of adaptive design methods in dialysis RCTs has decreased.
- 262 First, we report that the relative proportion of adaptive design methods in dialysis trials has reduced
- 263 over time. The absolute amount of dialysis trials using adaptive designs has increased each year, but
- this has not matched the overall increase in dialysis trials and therefore resulted in a relative
- 265 decrease. We were unable to compare this result with other specialities because recent systematic
- reviews have not reported the relative use of adaptive designs (20,23). Second, we report that group
- sequential designs are the most used type of adaptive design in dialysis trials. This is similar to
- previous systematic reviews in cardiology (24), oncology (23) and in a review of registered clinical
- trials covering multiple specialities on clinicaltrials.gov (20). Third, we report that adaptive designs
- 270 were more common in Acute Kidney Injury (AKI) (54% of trials) than End Stage Kidney Disease (ESKD)
- 271 (44% of trials). This may reflect increasing use of adaptive design methodology in critical care (25)
- and sepsis related trials (26), where AKI is most common. There were very few trials of CKD with a
- dialysis outcome (2%) that used an adaptive design. Many reasons for the paucity of CKD trials have
- been previously suggested including the use of treatments in CKD despite a lack of evidence,
- 275 difficulty recruiting to CKD trials due to stringent eligibility criteria and underpowered subgroup
- analysis (3,27). The infrequent usage of adaptive designs in CKD trials may become a self-
- 277 perpetuating barrier to using adaptive designs in future trials (20). Fourth, we report that adaptive
- design methods impacted the conduct of the randomised trial in the majority of studies (52%). For
- example, 18 (58.1%) trials were impacted by the use of group sequential adaptive design including 6
- trials (33.3%) stopped early for futility, 3 trials (16.7%) stopped early for efficacy and 4 trial (22.2%)
- stopped early for safety. This finding is similar to a systematic review of published and publicly
- available trials where the most common reason for stopping group sequential trials was futility (19).

283	Fifth, we found that most common country of the lead author was the United States of America, 20
284	studies (40%) and the most common funding source was public, 26 studies (52%). This finding was
285	different to a systematic review of published and publicly available trials where 65% of trials
286	reported industry funding (19). Funding for kidney research reached an all-time low in 2013 (4), but
287	this has recently changed in the United States with advocacy from scientific societies such as the
288	American Society of Nephrology, an executive order to reform the US End-Stage Kidney Disease
289	treatment industry was signed in 2020 (28). Adaptive designs are one part of the solution for
290	optimizing the design of clinical trials in dialysis and nephrology and will benefit from the
291	improvement in the funding landscape (27).
292	Limitations
293	Our study has several limitations. First, we limited our search to one database (Pubmed) due to the
294	scale of studies sourced (209,033 results). This was a deviation from our protocol but necessary to
295	make this full text review feasible. Second, we decided to include randomised clinical trials with RRT
296	outcomes in addition to patients currently on dialysis. This permitted a more comprehensive review
297	of the full landscape of AKI, ESKD and CKD trials, but was a deviation from our original protocol.
298	Third, the denominator for calculating the proportion of adaptive designs in all dialysis RCTs, will
299	include some false negatives i.e., either not RCTs or nor dialysis. We modified the parameters of the
300	machine learning classifier to perform a sensitive search to include as many true positives as
301	possible. We expect this mis-classification bias to be independent of time and bias every year equally
302	and therefore not affect the trend.
303	Strengths
304	We developed a novel full text systematic review search strategy. 41 studies (82%) did not report
305	their adaptive design method in the title or abstract and would not be detected by a standard
306	systematic review search methodology. This could introduce a pseudo reporting bias where adaptive

307 design methods are reported in the main paper but not in the abstract. Our novel strategy combined

- 308 classical systematic review, machine learning classifiers and a novel full text systematic review. This
- 309 new method has broad applications in medical evidence synthesis and evidence synthesis in general.

310 Conclusion

- 311 Adaptive design methods improve efficiency of randomised clinical trials in dialysis, but their relative
- 312 use is decreasing over time. Greater knowledge of adaptive design examples in dialysis will further
- 313 improve uptake in dialysis randomised clinical trials.

314

315 Author contributions

- 316 CJ, RM and MOD designed the study. CJ drafted the manuscript. CJ, RM, CR, SC, AS, MOH, MOD
- reviewed and approved the final version of the manuscript.

318 Acknowledgments

319 None

320 Disclosures

321 None

322 Funding

- 323 This work was performed within the Irish Clinical Academic Training (ICAT) Programme, supported
- by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health
- 325 Service Executive, National Doctors Training and Planning and the Health and Social Care, Research
- 326 and Development Division, Northern Ireland. The funding source had no role in the study design,
- 327 analysis or writing of report.

328 References

- Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the Gold Standard Lessons from
 the History of RCTs. N Engl J Med. 2016 Jun 2;374(22):2175–81.
- Kovesdy CP. Clinical trials in end-stage renal disease—priorities and challenges. Nephrol Dial
 Transplant. 2019 Jul 1;34(7):1084–9.
- Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, et al. Challenges in
 conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global
 Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017 Aug 1;92(2):297–305.
- Bryan L, Ibrahim T, Zent R, Fischer MJ. The Kidney Research Predicament. J Am Soc Nephrol
 JASN. 2014 May;25(5):898–903.
- Chatzimanouil MKT, Wilkens L, Anders H-J. Quantity and Reporting Quality of Kidney Research.
 J Am Soc Nephrol. 2019 Jan 1;30(1):13–22.
- 3406.Yaseen M, Hassan W, Awad R, Ashqar B, Neyra J, Heister T, et al. Impact of Recent Clinical341Trials on Nephrology Practice: Are We in a Stagnant Era? Kidney Dis. 2019;5(2):69–80.
- Chow S-C, Chang M, Pong A. Statistical Consideration of Adaptive Methods in Clinical
 Development. J Biopharm Stat. 2005 Jul 1;15(4):575–91.
- Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive
 designs in clinical trials: why use them, and how to run and report them. BMC Med [Internet].
 2018 Dec [cited 2020 Apr 23];16(1). Available from:
- 347 https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1017-7
- Research C for DE and. Adaptive Design Clinical Trials for Drugs and Biologics [Internet]. U.S.
 Food and Drug Administration. 2019 [cited 2019 Nov 18]. Available from:
 http://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design clinical-trials-drugs-and-biologics
- Novak JE, Inrig JK, Patel UD, Califf RM, Szczech LA. Negative trials in nephrology: what can we
 learn? Kidney Int. 2008 Nov;74(9):1121–7.
- Chaitman BR. Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise
 Tolerance and Angina Frequency in Patients With Severe Chronic AnginaA Randomized
 Controlled Trial. JAMA. 2004 Jan 21;291(3):309.
- Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in Patients
 with Type 2 Diabetes Mellitus Undergoing Hemodialysis. N Engl J Med. 2005 Jul 21;353(3):238–
 48.
- 13. Cheung BMY, Lauder IJ, Lau C-P, Kumana CR. Meta-analysis of large randomized controlled
 trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004
 May;57(5):640–51.
- Velenosi TJ, Urquhart BL. Pharmacokinetic considerations in chronic kidney disease and
 patients requiring dialysis. Expert Opin Drug Metab Toxicol. 2014 Aug;10(8):1131–43.

365 15. Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, et al. 366 TAILOR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An 367 Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of 368 Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clin Infect 369 Dis [Internet]. 2019 Jul 3 [cited 2020 Apr 23]; Available from: 370 https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz589/5527878 371 Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group. Preferred reporting items for 16. 372 systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009 Jul 21;339(jul21 373 1):b2535-b2535. 374 Judge C, Murphy RP, Cormican S, Smyth A, O'Halloran M, O'Donnell M. Adaptive design 17. 375 methods in dialysis clinical trials: a systematic review protocol. BMJ Open. 2020 Aug 376 27;10(8):e036755. 377 Beaubien-Souligny W, Kontar L, Blum D, Bouchard J, Denault AY, Wald R. Meta-analysis of 18. 378 Randomized Controlled Trials Using Tool-Assisted Target Weight Adjustments in Chronic 379 Dialysis Patients. Kidney Int Rep. 2019 Jul;S2468024919314044. 380 19. Bothwell LE, Avorn J, Khan NF, Kesselheim AS. Adaptive design clinical trials: a review of the 381 literature and ClinicalTrials.gov. BMJ Open. 2018 Feb 1;8(2):e018320. 382 Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs undertaken in clinical 20. 383 research: a review of registered clinical trials. Trials [Internet]. 2016 Dec [cited 2020 Aug 384 21];17(1). Available from: http://www.trialsjournal.com/content/17/1/150 385 21. Higgins JP. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). In RoB2 386 Development Group; 2019. Available from: 387 https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2 388 22. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane 389 Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343(oct18 390 2):d5928-d5928. 391 23. Mistry P, Dunn JA, Marshall A. A literature review of applied adaptive design methodology 392 within the field of oncology in randomised controlled trials and a proposed extension to the 393 CONSORT guidelines. BMC Med Res Methodol. 2017 Jul 18;17(1):108. 394 24. Clayton JA, Arnegard ME. Taking cardiology clinical trials to the next level: A call to action. Clin 395 Cardiol. 2018 Feb;41(2):179-84. 396 25. van Werkhoven CH, Harbarth S, Bonten MJM. Adaptive designs in clinical trials in critically ill patients: principles, advantages and pitfalls. Intensive Care Med. 2019 May 1;45(5):678-82. 397 398 26. Talisa VB, Yende S, Seymour CW, Angus DC. Arguing for Adaptive Clinical Trials in Sepsis. Front 399 Immunol [Internet]. 2018 Jun 28 [cited 2021 Jan 14];9. Available from: 400 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031704/ 401 Perkovic V, Craig JC, Chailimpamontree W, Fox CS, Garcia-Garcia G, Benghanem Gharbi M, et 27. 402 al. Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney Int 403 Suppl. 2017 Oct;7(2):138-44.

404 405 406 407	28.	Zoccali C, Vanholder R, Wagner CA, Anders H-J, Blankestijn PJ, Bruchfeld A, et al. Funding kidney research as a public health priority: challenges and opportunities. Nephrol Dial Transplant [Internet]. 2020 Sep 4 [cited 2021 Jan 14];(gfaa163). Available from: https://doi.org/10.1093/ndt/gfaa163
408 409 410	29.	Bove T, Zangrillo A, Guarracino F, Alvaro G, Persi B, Maglioni E, et al. Effect of Fenoldopam on Use of Renal Replacement Therapy Among Patients With Acute Kidney Injury After Cardiac Surgery: A Randomized Clinical Trial. JAMA. 2014 Dec 3;312(21):2244.
411 412 413 414	30.	Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet J-L, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013 Sep;39(9):1535–46.
415 416 417	31.	Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, et al. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med. 2018 Nov;379(18):1699– 710.
418 419 420 421	32.	Thiele H, Desch S, Piek JJ, Stepinska J, Oldroyd K, Serpytis P, et al. Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. Am Heart J. 2016 Feb;172:160–9.
422 423 424	33.	Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, et al. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med. 2017 May 25;376(21):2032–42.
425 426 427 428 429	34.	Mehta RH, Van Diepen S, Meza J, Bokesch P, Leimberger JD, Tourt-Uhlig S, et al. Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. Am Heart J. 2016 Dec;182:62–71.
430 431	35.	Intensity of Renal Support in Critically III Patients with Acute Kidney Injury. N Engl J Med. 2008 Jul 3;359(1):7–20.
432 433	36.	Sharma S, Kelly YP, Palevsky PM, Waikar SS. Intensity of Renal Replacement Therapy and Duration of Mechanical Ventilation. Chest. 2020 Oct;158(4):1473–81.
434 435 436	37.	Ejaz AA, Martin TD, Johnson RJ, Winterstein AG, Klodell CT, Hess PJ, et al. Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery. J Thorac Cardiovasc Surg. 2009 Oct;138(4):959–64.
437 438	38.	Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP. A trial of thyroxine in acute renal failure. Kidney Int. 2000 Jan;57(1):293–8.
439 440 441	39.	Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016 Jul 14;375(2):122–33.
442 443	40.	Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Tubach F, Pons B, et al. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for

444		a randomized controlled trial (AKIKI). Trials [Internet]. 2015 Dec [cited 2020 Oct 27];16(1).
445		Available from: http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-0718-x
446 447 448	41.	Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin S-S, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018 Feb 15;378(7):603–14.
449 450 451	42.	Schanz M, Wasser C, Allgaeuer S, Schricker S, Dippon J, Alscher MD, et al. Urinary [TIMP- 2]·[IGFBP7]-guided randomized controlled intervention trial to prevent acute kidney injury in the emergency department. Nephrol Dial Transplant. 2019 Nov 1;34(11):1902–9.
452 453 454 455 456	43.	Zarbock A, Küllmar M, Kindgen-Milles D, Wempe C, Gerss J, Brandenburger T, et al. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically III Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2020 Oct 27;324(16):1629.
457 458 459 460	44.	Meersch M, Küllmar M, Wempe C, Kindgen-Milles D, Kluge S, Slowinski T, et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ Open. 2019 Jan;9(1):e024411.
461 462 463	45.	Combes A, Bréchot N, Amour J, Cozic N, Lebreton G, Guidon C, et al. Early High-Volume Hemofiltration versus Standard Care for Post–Cardiac Surgery Shock. The HEROICS Study. Am J Respir Crit Care Med. 2015 Nov 15;192(10):1179–90.
464 465 466 467	46.	Robinson S, Zincuk A, Larsen UL, Ekstrøm C, Toft P. A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial. Trials [Internet]. 2014 Dec [cited 2020 Oct 27];15(1). Available from: https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-226
468 469 470	47.	Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically III Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 2016 May 24;315(20):2190.
471 472 473 474	48.	Zarbock A, Gerß J, Van Aken H, Boanta A, Kellum JA, Meersch M. Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial. Trials [Internet]. 2016 Dec [cited 2020 Oct 27];17(1). Available from: http://www.trialsjournal.com/content/17/1/148
475 476 477	49.	Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, et al. Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis: A Randomized Controlled Trial. JAMA. 2008 May 14;299(18):2164.
478 479 480	50.	Irish AB, Viecelli AK, Hawley CM, Hooi L-S, Pascoe EM, Paul-Brent P-A, et al. Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial. JAMA Intern Med. 2017 Feb 1;177(2):184.
481 482 483 484	51.	Viecelli AK, Polkinghorne KR, Pascoe EM, Paul-Brent P-A, Hawley CM, Badve SV, et al. Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. Puebla I, editor. PLOS ONE. 2019 Mar 26;14(3):e0213274.

485	52.	Chapman WC, Singla N, Genyk Y, McNeil JW, Renkens KL, Reynolds TC, et al. A Phase 3,
486		Randomized, Double-Blind Comparative Study of the Efficacy and Safety of Topical
487		Recombinant Human Thrombin and Bovine Thrombin in Surgical Hemostasis. J Am Coll Surg.
488		2007 Aug;205(2):256–65.

- 489 53. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive
 490 treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the
 491 ACCORD randomised trial. The Lancet. 2010 Aug;376(9739):419–30.
- Freedman BI, Wuerth J-P, Cartwright K, Bain RP, Dippe S, Hershon K, et al. Design and Baseline
 Characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy
 (ACTION II). Control Clin Trials. 1999 Oct;20(5):493–510.
- Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al. Antibacterial honey for the
 prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. Lancet
 Infect Dis. 2014 Jan;14(1):23–30.
- 498 56. Pascoe EM, Lo S, Scaria A, Badve SV, Beller EM, Cass A, et al. The Honeypot Randomized
 499 Controlled Trial Statistical Analysis Plan. Perit Dial Int J Int Soc Perit Dial. 2013 Jul;33(4):426–35.

57. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The Effects of
501 Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are
502 Receiving Hemodialysis and Epoetin. N Engl J Med. 1998 Aug 27;339(9):584–90.

- 50358.Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of Dipyridamole504plus Aspirin on Hemodialysis Graft Patency. N Engl J Med. 2009 May 21;360(21):2191–201.
- 505 59. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al. Angiotensin
 506 Blockade in Late Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2014 Dec
 507 11;371(24):2267-76.
- 60. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin
 and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun
 13;380(24):2295–306.
- 51161.Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and512Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347–57.
- 513 62. Knoll GA, Fergusson D, Chassé M, Hebert P, Wells G, Tibbles LA, et al. Ramipril versus placebo
 514 in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised
 515 controlled trial. Lancet Diabetes Endocrinol. 2016 Apr;4(4):318–26.
- Knoll GA, Cantarovitch M, Cole E, Gill J, Gourishankar S, Holland D, et al. The Canadian ACEinhibitor trial to improve renal outcomes and patient survival in kidney transplantation study
 design. Nephrol Dial Transplant. 2007 Aug 17;23(1):354–8.
- 64. Blankestijn PJ, Fischer KI, Barth C, Cromm K, Canaud B, Davenport A, et al. Benefits and harms
 of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose
 haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol. BMJ Open. 2020
 Feb;10(2):e033228.

523 65. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin
524 and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med. 2009 Apr
525 2;360(14):1395–407.

- 526 66. Fellström B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, et al. Effect of
 527 Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA
 528 Study. Kidney Blood Press Res. 2007;30(5):314–22.
- 67. Grooteman MPC, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AHA, et
 al. Effect of Online Hemodiafiltration on All-Cause Mortality and Cardiovascular Outcomes. J
 Am Soc Nephrol. 2012 Jun;23(6):1087–96.
- the CONTRAST study group, Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman
 MP, et al. Effect of increased convective clearance by on-line hemodiafiltration on all cause and
 cardiovascular mortality in chronic hemodialysis patients the Dutch CONvective TRAnsport
 STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125].
 Curr Control Trials Cardiovasc Med [Internet]. 2005 Dec [cited 2020 Oct 27];6(1). Available
 from: http://trialsjournal.biomedcentral.com/articles/10.1186/1468-6708-6-8
- Karunanithy N, Mesa IR, Dorling A, Calder F, Katsanos K, Semik V, et al. Paclitaxel-coated
 balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of
 arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised
 controlled trial. Trials [Internet]. 2016 Dec [cited 2020 Oct 27];17(1). Available from:
 http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1372-7
- Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, et al.
 OPPORTUNITYD: a large-scale randomized clinical trial of growth hormone in hemodialysis
 patients. Nephrol Dial Transplant. 2011 Dec 1;26(12):4095–103.
- 546 71. Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, et al.
 547 OPPORTUNITY[™]: A Randomized Clinical Trial of Growth Hormone on Outcome in Hemodialysis
 548 Patients. Clin J Am Soc Nephrol. 2008 Nov;3(6):1741–51.
- 549 72. Kwiatkowski DM, Goldstein SL, Cooper DS, Nelson DP, Morales DLS, Krawczeski CD. Peritoneal
 550 Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A
 551 Randomized Clinical Trial. JAMA Pediatr. 2017 Apr 1;171(4):357.
- 552 73. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, et al.
 553 Coronary Angiography after Cardiac Arrest without ST-Segment Elevation. N Engl J Med. 2019
 554 Apr 11;380(15):1397–407.
- 555 74. Lemkes JS, Janssens GN, Straaten HMO, Elbers PW, van der Hoeven NW, Tijssen JGP, et al.
 556 Coronary angiography after cardiac arrest: Rationale and design of the COACT trial. Am Heart J.
 557 2016 Oct;180:39–45.
- 55875.Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, et al. Fluid Response Evaluation559in Sepsis Hypotension and Shock. Chest. 2020 Oct;158(4):1431–45.
- Vinsonneau C, Camus C, Combes A, Costa de Beauregard MA, Klouche K, Boulain T, et al.
 Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal
 failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial.
 The Lancet. 2006 Jul;368(9533):379–85.

564 Pettilä V, Merz T, Wilkman E, Perner A, Karlsson S, Lange T, et al. Targeted tissue perfusion 77. 565 versus macrocirculation-guided standard care in patients with septic shock (TARTARE-2S): 566 study protocol and statistical analysis plan for a randomized controlled trial. Trials [Internet]. 2016 Dec [cited 2020 Oct 27];17(1). Available from: 567 568 http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1515-x 569 78. The ANDROMEDA-SHOCK Study Investigators, Hernández G, Cavalcanti AB, Ospina-Tascón G, 570 Zampieri FG, Dubin A, et al. Early goal-directed therapy using a physiological holistic view: the 571 ANDROMEDA-SHOCK—a randomized controlled trial. Ann Intensive Care [Internet]. 2018 Dec 572 [cited 2020 Oct 27];8(1). Available from: 573 https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-018-0398-2 574 79 Tumlin JA, Galphin CM, Tolwani AJ, Chan MR, Vijayan A, Finkel K, et al. A Multi-Center, 575 Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective 576 Cytopheretic Device in Patients with Acute Kidney Injury. Cravedi P, editor. PLOS ONE. 2015 577 Aug 5;10(8):e0132482. 578 Riley AA, Jefferies JL, Nelson DP, Bennett MR, Blinder JJ, Ma Q, et al. Peritoneal Dialysis does 80. 579 not Adversely Affect Kidney Function Recovery after Congenital Heart Surgery. Int J Artif 580 Organs. 2014 Jan;37(1):39-47. 581 Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, et al. Darbepoetin Alfa in 81. 582 Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. Clin J Am Soc 583 Nephrol. 2020 May 7;15(5):608–15. 584 82. Imai E, Maruyama S, Nangaku M, Hirakata H, Hayashi T, Narita I, et al. Rationale and study 585 design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels 586 using darbepoetin alfa on prevention of development of end-stage kidney disease in non-587 diabetic CKD patients (PREDICT Trial). Clin Exp Nephrol. 2016 Feb;20(1):71–6. 588 83. Marsen TA, Beer J, Mann H. Intradialytic parenteral nutrition in maintenance hemodialysis patients suffering from protein-energy wasting. Results of a multicenter, open, prospective, 589 590 randomized trial. Clin Nutr. 2017 Feb;36(1):107-17. 591 84. Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F. A Phase 3 Trial of Difelikefalin in 592 Hemodialysis Patients with Pruritus. N Engl J Med. 2020 Jan 16;382(3):222–32. 593 85. Kammerer T, Brettner F, Hilferink S, Hulde N, Klug F, Pagel J-I, et al. No Differences in Renal 594 Function between Balanced 6% Hydroxyethyl Starch (130/0.4) and 5% Albumin for Volume 595 Replacement Therapy in Patients Undergoing Cystectomy. Anesthesiology. 2018 Jan 596 1;128(1):67-78. 597 86. Kammerer T, Klug F, Schwarz M, Hilferink S, Zwissler B, von Dossow V, et al. Comparison of 6 % 598 hydroxyethyl starch and 5 % albumin for volume replacement therapy in patients undergoing 599 cystectomy (CHART): study protocol for a randomized controlled trial. Trials [Internet]. 2015 600 Dec [cited 2020 Oct 27];16(1). Available from: 601 http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-0866-z 602 87. Kratochwill K, Boehm M, Herzog R, Gruber K, Lichtenauer AM, Kuster L, et al. Addition of 603 Alanyl-Glutamine to Dialysis Fluid Restores Peritoneal Cellular Stress Responses – A First-In-604 Man Trial. Eller K, editor. PLOS ONE. 2016 Oct 21;11(10):e0165045.

605	88.	Fujimoto K, Adachi H, Yamazaki K, Nomura K, Saito A, Matsumoto Y, et al. Comparison of the
606		pain-reducing effects of EMLA cream and of lidocaine tape during arteriovenous fistula
607		puncture in patients undergoing hemodialysis: A multi-center, open-label, randomized
608		crossover trial. Wu P-H, editor. PLOS ONE. 2020 Mar 25;15(3):e0230372.

- 89. Himmelfarb J, Chertow GM, McCullough PA, Mesana T, Shaw AD, Sundt TM, et al.
 Perioperative THR-184 and AKI after Cardiac Surgery. J Am Soc Nephrol. 2018 Feb;29(2):670–9.
- 90. Hosgood SA, Saeb-Parsy K, Wilson C, Callaghan C, Collett D, Nicholson ML. Protocol of a
 randomised controlled, open-label trial of ex vivo normothermic perfusion versus static cold
 storage in donation after circulatory death renal transplantation. BMJ Open. 2017
 Jan;7(1):e012237.
- Bestle MH, Clausen NE, Søe-Jensen P, Kristiansen KT, Lange T, Johansson PI, et al. Efficacy and
 safety of iloprost in patients with septic shock-induced endotheliopathy—Protocol for the
 multicenter randomized, placebo-controlled, blinded, investigator-initiated trial. Acta
 Anaesthesiol Scand. 2020 May;64(5):705–11.
- 92. Pickkers P, Mehta RL, Murray PT, Joannidis M, Molitoris BA, Kellum JA, et al. Effect of Human
 Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With SepsisAssociated Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2018 Nov 20;320(19):1998.
- 622 93. E P, RL M, PT M, J H, M J, JA K, et al. Study protocol for a multicentre randomised controlled
 623 trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline
 624 Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI). BMJ Open.
 625 2016;6(9):e012371.
- 626 94. Kassimatis T, Qasem A, Douiri A, Ryan EG, Rebollo-Mesa I, Nichols LL, et al. A double-blind
 627 randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing
 628 ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a
 629 randomised controlled trial. Trials [Internet]. 2017 Dec [cited 2020 Oct 27];18(1). Available
 630 from: http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-1972-x

631

632

634 Table 1 – Groups Sequential Trials in Dialysis Randomized Clinical Trials

A	<u>Study Name,</u> <u>Year</u> cute Kidney Injury	<u>Stopping</u> <u>Rule</u>	<u>Impact of Adaptive</u> <u>design</u>	Population	Intervention	<u>Primary Outcome</u>	<u>Nature of</u> primary outcome	<u>Dialysis</u> Modality	<u>Sample</u> <u>Size of</u> <u>Study</u>	<u>Country of</u> <u>lead</u> investigator	<u>Funder</u>	<u>Funder Details</u>	Study of Phase of All
	FENO HSR, 2014, (29)	Reboussin et al and Lan-DeMets Stopping Rule	Stopped due to futility after the 3rd interim analysis.	Critically ill cardiac surgery patients with acute kidney injury	Fenoldopam	Rate of renal replacement therapy.	Hard clinical	Any RRT	667	Italy	Public	Grant from the Italian Ministry of Health	Phats reserve
	IVOIRE, 2013, (30)	Not reported	One interim analysis performed as planned, trial d/c due to difficulty recruiting.	Critically ill patients with septic shock and AKI.	High-volume HF (HVHF)	28-day mortality	Hard clinical	HF	140	France	Public	Grant from the French Health Ministry	Phase No reuse a
	CULPRIT- SHOCK, 2018, (31,32)	O Brien- Fleming boundary	NA	Patients with cardiogenic shock complicating acute myocardial infarction.	Culprit lesion only Primary Coronary Intervention.	30-day mortality or AKI requiring RRT.	Hard clinical	HD/HDF	706	Germany	Public	EU; German Heart Research Foundation; German Cardiac Society.	Phamed witho
	LEVO-CTS, 2017, (33,34)	O Brien- Fleming boundary	Not reported.	Patients with a EF<35% who were undergoing cardiac surgery with the use of cardiopulmonary bypass.	Intraven ous Ievosimen dan	Composite of 30-day mortality, RRT, perioperative MI, or mechanical cardiac assist device through day 5.	Hard clinical	HD/HDF	882	USA	Private	Tenax Therapeutics	Ph Ⅲ
	ATN, 2008, (35,36)	Haybittle- Peto rule	Two interim analyses performed as planned, trial continued per protocol.	Critically ill patients with acute kidney injury and failure of at least one nonrenal organ or sepsis.	Intensive or less intensive renal- replacement therapy.	Death from any cause by day 60	Hard clinical	HD/HDF	1124	USA	Public	Cooperative Studies Program VA and by the NIDDKD.	Phase Copy III Spray
	Ejaz et al., 2009, (37)	Z-boundary	The study was stopped after completion of stage I.	Patients undergoing high-risk cardiac surgery.	Nesiritide	Dialysis and/or all- cause mortality within 21 days.	Hard clinical	HD	94	USA	Private	Scios, Inc.	Phase c

												(which
Acker et al., 2000, (38)	Pocock	Significant difference in mortality was observed at first analysis and trial was terminated.	Patients with acute renal failure.	Thyroxine	Percentage requiring dialysis.	Hard clinical	HD/HDF	59	USA	Not reported	Not reported	Phase was not certifie
AKIKI, 2016, (39,40)	O Brien- Fleming boundary	Two interim analysis before final analysis. No change to trial.	Patients with severe acute kidney injury who required mechanical ventilation, catecholamine infusion, or both.	Early or a delayed strategy of renal- replacement therapy.	Overall survival at day 60.	Hard clinical	HD	620	France	Public	Funded by the French Ministry of Health	Phase d by peer III peer reviev
PRESERVE, 2018, (41)	O Brien- Fleming boundary	The sponsor stopped the trial after a prespecified interim analysis.	Patients at high risk for renal complications who were scheduled for angiography.	1.26% sodium bicarbonate or intravenous 0.9% sodium chloride and 5 days of oral acetylcysteine or oral placebo.	Composite of death, the need for dialysis, or a persistent increase of at least 50% from baseline in the serum creatinine level at 90 days.	Hard clinical	HD	5177	USA	Public	U.S. Department of Veterans Affairs Office of Research and Development and the National Health and Medical Research Council of Australia.	v) is the author/funder, wh All rights reserved. No reu ha≡
Schanz et al., 2019, (42)	Jenni son and Turnbull	The study was stopped prematurely after interim analysis.	Patients at high risk for AKI.	Screened with urinary [TIMP- 2][IGFBP7]	Incidence of moderate to severe AKI within the first day after admission.	Surrogate	HD	100	Germany	Public	Robert-Bosch- Foundation	no has grar use allowe Ⅲ
RICH, 2020, (43,44)	O Brien- Fleming boundary	The interim analysis showed that the preplanned end of the trial according to the protocol was reached before the complete number of patients was recruited	Critically III Patients With Acute Kidney Injury	Regional citrate anticoagulation, compared with systemic heparin anticoagulation.	Filter life span and 90-day mortality	Hard clinical	HDF	596	Germany	Public	German Research Foundation	nted medRxiv a license davithout permission. Ph ≣
HEROI <i>C</i> S, 2015, (45)	Triangular test (Whitehead 1978)	At the third sequential interim analysis the trial was stopped for futility.	Patients with severe shock requiring high- dose catecholamines 3 "24 h postcardiac surgery.	Early high volume haemofiltration	30-day mortality	Hard clinical	HF/HDF	224	France	Public and Private	French Ministry of Health and Hospal-Gambro.	Phase display the
FBI, 2014, (46) Protocol	Fleming- Harrington (O Brien- Fleming boun dary)	NA	Critically ill patients with acute kidney injury receiving continuous renal replacement therapy.	Enoxaparin	Occurrence of venous thromboembolism.	Hard clinical	HD/HDF/HF	266	Denmark	Public	Danish society of anesthesiology & intensive medicine's research initiative	Phase reprint in perpetuity.

												nich
ELAI N-Tri 2016, (47	ial, O Brien- 7,48) Fleming boundary	One interim analysis was performed after half of the total number of deaths across both treatment groups.	Critically ill patients with AKI and plasma neutrophil gelatinase "associated lipocalin level higher than 150 ng/mL.	Early or delayed initiation of RRT.	Mortality at 90 days	Hard clinical	HD/HDF/HF	231	Germany	Private	Else Kröner Fresenius Stiftung	Phase Was not certile
<u>End Stage Ki</u>	dney Disease											0 0
DAC, 200 (49)	8, Lan-DeMets (OBrien- Fleming boundary)	NA	Participants with ESKD and undergoing new fistula creation.	Clopidogrel	Fistula thrombosis	Surrogate	HD	877	USA	Public	National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.	Phase Phase Phase Phase All rig All rig
FAVOURE 2017, (50	ED, Haybittle-),51) Petorule	Early cessation of recruitment, only 1st interim analysis was performed.	Participants with stage 4 or 5 chronic kidney disease after arteriovenous fistula creation.	Fish oil supplementation	Fistula failure, a composite of fistula thrombosis and/or abandonment and/or cannulation failure, at 12 months	Hard clinical	HD	567	Australia	Public and Private	Grants from National Health and Medical Research Council of Australia, Amgen Australia Pty Ltd and Mylan EPD.	ne autnor/tunder, wn jigts reserved. No reu ₽ ≡
Chapman al., 2007,	n et Constrained (52) stopping boundaries	Two interim analysis, trial continued.	Liver resection, spine, peripheral arterial bypass, and dialysis access surgery.	Recombinant human thrombin (rhThrombin)	Time to hemostasis	Surrogate	HD	76	USA	Private	ZymoGenetics, Inc	no nas gran Phase allower ⊫
A CCORD, 2010, (53	Lan-DeMets	Intensive therapy was stopped before study end due to increased mortality.	Volunteers with established T2DM, HbA1c∣evels ≥ 7.5% and CVD or two or more CVD risk factors	Target HbA1c of <6.0%.	Dialysis or renal transplantation, or serum creatinine >291.7 micromol/L, or retinal photocoagulation or vitrectomy.	Hard clinical	HD	10251	USA	Public	National Heart, Lung, and Blood Institute.	hted medRxiv a lice dwithout permissic h ≣
ACTION 1999, (54 Protocol	l, Lan-DeMets I),	ACTION terminated enrollment	Type 2 diabetic patients with renal disease.	Aminoguanidine	Doubling of serum creatinine concentration.	Surrogate	HD	900	USA	Not reported	Not reported	Phase to o
HONEYP(2014, (55	OT, Haybittle- 5,56) Petorule	Stopping rule for efficacy was not met, and the study was completed as per protocol	Participants undergoing PD	Daily topical exit- site application of antibacterial honey	Time to first infection related to PD	Hard clinical	PD	371	Australia	Public an d Private	Baxter Healthcare, Queensland Government, Comvita, and Gambro.	Phase

												ŝ
Besarab e 1998, (57)	et al., Lan-DeM ets) (O Brien- Fleming boundary)	The trial was stopped at the third interim analysis.	Patients with clinical evidence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis.	Epoetin and target hematocrit.	Length of time to death or a first nonfatal myocardial infarction.	Hard clinical	HD	1233	USA	Private	Amgen	Phase Phase III
DAC, 2009 (58)	9, Lan-DeMets (Wang- Tsiatis boundary)	Five planned interim analyses were performed before the final analysis. No change to trial.	Participants with placement of a new arteriovenous graft.	Exten ded-release dipyridamole plus aspirin	Loss of primary unassisted patency	Hard clinical	HD	649	USA	Public and Private	NIDDKD, NIH, and Boehringer Ingelheim.	Phase d by peer rev
HALT-PKD 2014, (59)	0, Lan-DeMets) (O Brien- Fleming boundary)	The study was extended due to a lower-than- expected number of end points.	Patients with autosomal dominant polycystic kidney disease.	Lisinopril and telmisartan	Time to death, end- stage renal disease, or a 50% reduction from the baseline estimated GFR.	Hard clinical	HD	486	USA	Public	NIDDKD	view) is the au Phase All rights u Ph ⊞
CREDEN C 2019, (60)	E, Alpha) spending function	The prespecified efficacy criteria for early cessation had been achieved and recommended that the trial be stopped.	Patients with type 2 diabetes and albuminuric chronic kidn <i>e</i> y disease.	Can ag lifl o zin	Composite of end- stage kidney disease (dialysis, transplantation, sustained GFR <15), a doubling of the serum creatinine level, or death from renal or cardiovascular causes.	Both	HD	4401	Australia	Private	Janssen Research and Development	uthor/funder, who has grante regerved. No reuse allowed v Ph ≡
DECLARE "TIMI 58, 2019, (61)	O Brien- Fleming) boundary	NA	Patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease.	Dapagiiflozin	Cardiovascular death, myocardial infarction, or ischemic stroke or hospitalization for heart failure.	Hard clinical	HD	17160	USA	Private	AstraZeneca	d medRxiv a lice vi∰nout permissio Ph ≣
Knoll et al 2015, (62,	I., O Brien- ,63) Fleming boundary	NA	Kidney transplant patients with proteinuria and an estimated GFR 20-55 ml/min/1.73 m2.	Ramipril	Doubling of serum creatinine, end stage renal disease or death.	Both	HD	528	Can ada	Public	Canadian Institutes of Health Research.	Phase to displa
CONVINC 2020, (64) Protocol	E, Haybittle-), Peto rule	Trial not complete.	Patents with ESKD treated with HD.	High-dose HDF versus conventional high-flux HD.	All-cause mortality	Hard clinical	HD/HDF	1800	Th e Netherian ds	Public	European Union's Horizon 2020 research and innovation programme.	Phase Phase III

												5
AURORA, 2009, (65,66)	Event- driven	Continuation of the study was recommended by the data and safety monitoring board.	Patients who were undergoing maintenance hemodialysis.	Rosuvastatin	Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke	Hard clinical	HD	2776	Sweden	Private	AstraZen eca	Phase III III
CONTRAST, 2012, (67,68)	Double triangular test (Whitehead 2007)	The board recommended to stop the trial because enough evidence was provided for futility.	Patients with ESRD.	Online hemodiafiltration.	All-cause mortality	Hard clinical	HD/HDF	714	Th e N et h er an ds	Public an d Private	Dutch Kidney Foundation, Fresenius Medical Care, and Gambro Lundia.	Phase Ⅲ Ⅲ
PAVE, 2016, (69), Protocol	Lan-DeMets (OBrien- Fleming boundary)	Trial not complete.	Patients with a native arteriovenous fistula.	Paclit ax el- coat ed balloon s	Time to end of target lesion primary patency.	Surrogate	HD	211	United Kingdom	Public	National Institute for Health Research (NIHR) EME programme	Phasell rights n ⊫ Phasell rights n
OPPORTUNITY, 2011, (70,71)	Event- driven	NA	Adult maintenance hemodialysis patients.	Recombinant human growth hormone.	Mortality	Hard clinical	HD	695	USA	Private	Novo Nordisk	Phaserved Phaserved

635 Figure 1 Legend – HD – Haemodialysis, HDF – Haemodiafiltartion, HF – Haemofiltration, PD – Peritoneal Dialysis

636

medRxiv preprint doi: https://doi.org/10.1101/2021.01.22.21250343; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

637 Table 2 – Sample-Size Re-estimation in Dialysis Randomized Clinical Trials

	<u>Study Name,</u> <u>Year</u>	<u>Impact of Adaptive</u> <u>design</u>	Population	Intervention	<u>Primary Outcome</u>	<u>Nature of</u> primary outcome	<u>Dialysis</u> <u>Modality</u>	<u>Sample</u> <u>Size of</u> <u>Study</u>	<u>Country of</u> <u>lead</u> investigator	<u>Funder</u>	<u>Funder Details</u>	<u>Study</u> <u>Phase</u>	
<u>s</u>	Sample-Size Re-estimation												
<u>A</u>	<u>cute Kidney Injury</u> Kwiatkowski et al., 2017, (72)	r Not reported.	Infants after congenital heart surgery.	PD	Negative Fluid Balance	Surrogate	PD	73	USA	Public	American Heart Association "Great Rivers Affiliate and internal funding from Cincinnati Childrens Hospital Medical Center.	Phase II	
	COACT, 2019, (73,74)	After this interim analysis, the data and safety monitoring committee advised that the sample size not be increased.	Post "cardiac arrest patients without signs of STEMI.	Immediate coronary angiography and percutaneous coronary intervention.	90-day mortality	Hard clinical	HD/HDF	552	Th e N eth er I an ds	Public	Netherlands Heart Institut e.	Phase 	
	FRESH, 2020, (75)	NA	Patients presenting to the ED with sepsis or septic shock and anticipated ICU admission.	Dynamic assessment of fluid responsiveness (passive leg raise).	Difference in positive fluid balance at 72 hours or ICU discharge.	Surrogate	HD/HDF/HF	124	USA	Privat e	Cheetah Medical	Phase 	
	Hemodiafe, 2006, (76)	The sample size was adjusted to include 180 patients per group.	Critically ill patients with acute renal failure as part of multiple- organ dysfunction syndrome.	Intermittent HD versus continuous venovenous HDF	60-day survival	Hard clinical	HD/HDF	360	France	Public	Supported by the Societe de Reanimation de Langue Francaise, with a grant from the Delegation a la Recherche Clinique de l'Assistance Publique-Hopitaux de Paris (Projet Hospitalier de Recherche Clinique) and Hospal Inc (Lyon, France).	Phase III	

	TARTARE-2S, 2016, (77), Protocol	Trial not complete.	Patients with septic shock.	Targeted tissue perfusion versus macrocirculation- guided stan dard care	Alive at 30 days with normal arterial blood lactate and without any inotropic or vasopressor agent.	Hard clinical	HD/HDF/HF	200	Switzerland	Public	Sigrid Juselius Foundation, Instrumentarium Foundation, and Helsinki University Hospital	Phase
	ANDROMEDA- SHOCK, 2018, (78), Protocol	Trial not complete.	Patients with septic shock.	Peripheral perfusion 'targeted resuscitation	28 ' day mort ality	Hard clinical	HD/HDF/HF	422	Chile	Public	Departamento de Medicina Intensiva, Pontificia Universidad Católica de Chile.	Phase
	SCD, 2015, (79)	The study was terminated by the sponsor at the interim analysis because the SCD treatment was often outside the recommended iCa range, and therefore, resulted in ineffective ther apy	ICU patients with AKI	Selective Cytopheretic Device	60-day mortality	Hard clinical	HDF	134	USA	Privat e	CytoPherx, Inc.	Phase
	Ril ey et al., 2014, (80)	Data from the initial ten randomized patients demonstrated >50% difference in urine output, revealing adequate power would be achieved with only 20 randomized patients.	Infants <90 days old with congenital heart disease who underwent bypass surgery and were post-operatively treated with CPD.	Continue 24 h more CPD or discontinue CPD.	Urine output (ml/kg per h)	Surrogate	PD	20	USA	Public	Baylor College of Medicine and Cincinnati Children ™s Hospital Medical Center.	Phase
En	d Stage Kidney Di	<u>sease</u>										
	PREDICT, 2020, (81,82)	The sample size was amended from 220 to 238 for each group.	Patients with CKD without diabetes.	High and low hemoglobin groups (Darbepoetin alfa)	Kidney composite end point (starting maintenance dialysis, kidney transplantation, eGFR<6 ml/min per 1.73 m2, and 50% reduction in eGFR).	Both	HD	491	Japan	Privat e	Kyowa Hakko Kirin, Otsuka, Dainippon Sumitomo, and Mochida.	Phase
	IDPN-Trial, 2017, (83)	Sample size was increased. Primary outcome was significant.	Maintenance hemodialysis patients suffering from Protein- energy wasting (PEW).	Intradialytic parenteral nutrition (IDPN)	Prealbumin	Surrogate	HD	107	Germany	Private	Fresenius Kabi Germany GmbH, Bad Homburg, Germany.	Phase IV

KALI 2019	M-1, 9, (84)	Not reported	Patients undergoing hemodialysis who had moderate-to-severe pruritus.	Intravenous difelikefalin	24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS)	Surrogate	HD	378	USA	Private	Cara Therapeutics	Phase
CHA (85,	ART, 2018, 86)	NA	Urologic patients undergoing elective cystectomy.	Albumin 5% or balanced hydroxyethyl starch 6%	Ratio of serum cystatin C between the last visit at day 90 and the first preoperative visit.	Surrogate	HD	100	Germany	Private	CSL Behring GmbH	Phase III
Krat al., 2	:och will et 2016, (87)	Led to premature termination of patient recruitment	Stable PD outpatients.	Alanyl-glutamine addition to glucose- based PD Fluid.	Heat-shock protein 72 expression	Surrogate	PD	20	Austria	Public	ZIT - Technology Agency of the City of Vienna and FFG - the Austrian Research Promotion Agency	Phase
Fujir al., 2	moto et 2020, (88)	The sample size was calculated by the intermediate analysis of the first 30 samples enrolled.	Patients undergoing maintenance hemodialysis thrice/week.	Lidocaine/prilocaine cream (EMLA).	Puncture pain relief, which was measured using a 100-mm visual analog scale.	Surrogate	HD	66	Taiwan	Public	Grant-in-Aid for Young Scientists from the Japan Society for the Promotion of Science.	Phase II

638

639 Figure 2 Legend – HD – Haemodialysis, HDF – Haemodiafiltartion, HF – Haemofiltration, PD – Peritoneal Dialysis

640

641

642 Table 3 – Seamless Design/Adaptive Dose-Escalation in Dialysis Randomized Clinical Trials

	<u>Study Name,</u> <u>Year</u>	<u>Impact of Adaptive</u> <u>design</u>	<u>Population</u>	Intervention	<u>Primary Outcome</u>	<u>Nature of</u> primary outcome	<u>Dialysis</u> Modality	<u>Sample</u> <u>Size of</u> <u>Study</u>	<u>Country of</u> lead investigator	<u>Funder</u>	<u>Funder Details</u>	<u>Study</u> <u>Phase</u>		
Sea	Sea mless Design/Adaptive Dose-Escalation													
<u>Acu</u>	te Kidney Injury													
	<u>Two-stage seam</u>	less adaptive design												
	Himmelfarb et al., 2018, (89)	At the end of each stage, data from the patients are used to select the THR-184 dose arms for next stage.	Patients at high risk for AKI after cardiac surgery.	THR-184	Proportion of patients who developed AKI	Hard clinical	HD/HDF/HF	452	USA	Private	Thrasos Therapeutics, Inc.	Phase		
	<u>Interim analysis</u>													
	Hosgood et al., 2017, (90), Protocol	Trial not complete.	Patients receiving a kidney from a donation after circulatory death donor.	Ex vivo normothermic perfusion	Rates of delayed graft function (DGF) defined as the need for dialysis in the first week post- transplant.	Surrogate	HD	400	United Kingdom	Public	Kidney Research UK; University of Cambridge and University Hospitals of Cambridge Foundation Trust.	Phase		
	<u>Phase / seam</u>	less design												
	COMBAT- SHINE, 2020, (91), Protocol	Trial not complete.	Patients with septic shock-induced en dotheliopathy.	Infusion of iloprost	Mean daily modified Sequential Organ Failure Assessment (SOFA) score	Surrogate	HD	384	Denmark	Public	Danish Independant Research Organisation	Phase		
	<u>Phase IIa/IIb sea</u>	mless design												
	STOP-AKI, 2018, (92,93)	ΝΑ	Critically ill patients with sepsis associated AKI.	Human recombinant alkaline phosphatase	Area under the time corrected endogenous creatinine clearance curve from days 1 to 7.	Surrogate	HD	301	The Netherlands	Private	AM-Pharma	Phase IIa/IIb		
	Adaptive Dose-E	scalation												
	EMPIRIKAL, 2017, (94), Protocol	Trial not complete.	Patients after receiving cadaveric renal allografts.	Mirococept	Delayed graft function	Surrogate	HD/HDF/HF	560	United Kingdom	Public	Medical Research Council	Phase		

643 Figure 3 Legend – HD – Haemodialysis, HDF – Haemodiafiltartion, HF – Haemofiltration, PD – Peritoneal Dialysis

644 Figures

645 Figure 1 – PRISMA Flow Diagram





647 Figure 2 – Adaptive Design in Dialysis Randomized Clinical Trials by Year



649 Figure 3 – Populations with Adaptive Design in Dialysis Randomized Clinical Trials by Year

650





